Boston Therapeutics, Inc.
Boston Therapeutics, Inc. (BTHE) Stock Ownership
Latest 13F position summary is not yet available — breakdown and tables fill in after filings publish (typically ~45 days after quarter end).
SEC 13F · FMP · BTHE · as of —
Ownership Breakdown
Institutional data for this period is not yet available. SEC Form 13F filings are typically published 45 days after quarter end.
No institutional data available for this period.
Insider Buying vs Selling
BTHE insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
RAUSCH CARL W Chief Executive Officer | Feb 2, 2018 | Purchase | 2,000,000 | $0.15 | $300.0K | 2.00M | Form 4 ↗ |
RAUSCH CARL W Chief Executive Officer | Feb 2, 2018 | Purchase | 1,000,000 | $0.10 | $100.0K | 1.00M | Form 4 ↗ |
CONAWAY DALE H director | May 15, 2015 | Purchase | 5,000 | $0.12 | $600 | 7.1K | Form 4 ↗ |
PLATT DAVID CEO and Chairman | May 15, 2015 | Purchase | 1,000 | $0.15 | $147.6 | 7.56M | Form 4 ↗ |
PLATT DAVID CEO and Chairman | May 14, 2015 | Purchase | 5,000 | $0.12 | $600 | 7.56M | Form 4 ↗ |
ESBER HENRY JEMIL director | Sep 25, 2014 | Award | 6,000 | $0.37 | $2.2K | 228.0K | Form 4 ↗ |
ESBER HENRY JEMIL director | Mar 18, 2015 | Purchase | 9,000 | $0.20 | $1.8K | 13.0K | Form 4 ↗ |
SQUEGLIA ANTHONY DON Chief Financial Officer | Mar 10, 2015 | Purchase | 10,000 | $0.22 | $2.2K | 128.3K | Form 4 ↗ |
PLATT DAVID CEO and Chairman | Mar 9, 2015 | Purchase | 1,250 | $0.24 | $306.25 | 7.56M | Form 4 ↗ |
PLATT DAVID CEO and Chairman | Mar 9, 2015 | Purchase | 465 | $0.24 | $111.6 | 7.55M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Boston Therapeutics, Inc. (BTHE) is primarily owned by institutional investors, who hold approximately — of total shares outstanding. Company insiders own approximately —, while retail and public investors account for the remaining —.
A total of 0 institutional investors currently hold BTHE stock, with a combined institutional value of approximately $0 as of the most recent 13F filing period.
Frequently asked questions
BTHE ownershipBoston Therapeutics, Inc. (BTHE) is primarily owned by institutional investors, who hold approximately — of shares. The largest shareholder is — with a — stake. Company insiders hold —. Data sourced from SEC Form 13F as of —.